Yunzi Wang1, Jingping Xiao2, Yuanyu Zhao1, Shijuan Du1, Jiang Du3. 1. Department of Pathology, Sichuan Science City Hospital, Mianyang, 621000, Sichuan, China. 2. Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, 621000, Sichuan, China. xiaojingping5@126.com. 3. Department of General Surgery, Sichuan Science City Hospital, Mianyang, 621000, Sichuan, China.
Abstract
PURPOSE: To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM). METHODS: We searched Medline, PubMed, EMBASE, Clinical Trials.gov (http://www.clinicaltrials.gov), and the Cochrane Collaboration Library from inception to November 2019. To analyze the relationship between metformin and the overall mortality, specific mortality, and sex differences in CRC patients with T2DM, hazard ratios (HRs) with 95% confidence intervals (CIs) were used. Egger's test and Begg's test were used to assess publication bias. RESULTS: We included 8 cohort studies in our meta-analysis. CRC patients with T2DM treated with metformin had a lower overall mortality than CRC patients with T2DM who did not receive metformin (HR = 0.80, 95% CI 0.67-0.95). There was no significant difference in CRC-specific mortality between CRC patients with T2DM who used metformin and those who did not (HR = 0.84, 95% CI 0.65-1.08). However, females had a lower CRC-specific mortality among CRC patients with T2DM than males (HR = 0.63, 95% CI 0.41-0.97). CONCLUSION: Metformin reduced the overall mortality of CRC patients with T2DM. Moreover, female CRC patients with T2DM using metformin had lower CRC-specific mortality than male CRC patients with T2DM.
PURPOSE: To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM). METHODS: We searched Medline, PubMed, EMBASE, Clinical Trials.gov (http://www.clinicaltrials.gov), and the Cochrane Collaboration Library from inception to November 2019. To analyze the relationship between metformin and the overall mortality, specific mortality, and sex differences in CRCpatients with T2DM, hazard ratios (HRs) with 95% confidence intervals (CIs) were used. Egger's test and Begg's test were used to assess publication bias. RESULTS: We included 8 cohort studies in our meta-analysis. CRCpatients with T2DM treated with metformin had a lower overall mortality than CRCpatients with T2DM who did not receive metformin (HR = 0.80, 95% CI 0.67-0.95). There was no significant difference in CRC-specific mortality between CRCpatients with T2DM who used metformin and those who did not (HR = 0.84, 95% CI 0.65-1.08). However, females had a lower CRC-specific mortality among CRCpatients with T2DM than males (HR = 0.63, 95% CI 0.41-0.97). CONCLUSION:Metformin reduced the overall mortality of CRCpatients with T2DM. Moreover, female CRCpatients with T2DM using metformin had lower CRC-specific mortality than male CRCpatients with T2DM.
Entities:
Keywords:
Colorectal cancer; Meta-analysis; Metformin; Mortality; Sex difference; T2DM
Authors: Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh Journal: Colorectal Cancer Date: 2017-06-21
Authors: Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost Journal: Cancer Res Date: 2011-05-03 Impact factor: 12.701
Authors: Furha Iram Cossor; Lucile L Adams-Campbell; Rowan T Chlebowski; Marc J Gunter; Karen Johnson; Robert E Martell; Anne McTiernan; Michael S Simon; Thomas Rohan; Robert B Wallace; Jessica K Paulus Journal: Cancer Epidemiol Date: 2013-06-15 Impact factor: 2.984
Authors: M M J Zanders; M P P van Herk-Sukel; P A J Vissers; R M C Herings; H R Haak; L V van de Poll-Franse Journal: Br J Cancer Date: 2015-07-16 Impact factor: 7.640
Authors: Eusebio Chiefari; Maria Mirabelli; Sandro La Vignera; Sinan Tanyolaç; Daniela Patrizia Foti; Antonio Aversa; Antonio Brunetti Journal: Int J Mol Sci Date: 2021-10-15 Impact factor: 5.923